Pharvaris (NASDAQ:PHVS) Hits New 12-Month High – Should You Buy?

Pharvaris N.V. (NASDAQ:PHVS)’s stock price hit a new 52-week high on Thursday . The company traded as high as $34.43 and last traded at $34.0050, with a volume of 7619 shares trading hands. The stock had previously closed at $33.29.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PHVS. Wall Street Zen upgraded shares of Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Citigroup reissued a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Morgan Stanley reaffirmed an “overweight” rating and set a $46.00 price target on shares of Pharvaris in a research report on Thursday. Royal Bank Of Canada decreased their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Finally, HC Wainwright restated a “buy” rating on shares of Pharvaris in a report on Tuesday, June 16th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.64.

Pharvaris Stock Performance

The firm has a market cap of $2.25 billion, a price-to-earnings ratio of -10.85 and a beta of -2.35. The stock has a 50-day moving average of $30.37 and a 200-day moving average of $27.88.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. Sell-side analysts predict that Pharvaris N.V. will post -3.22 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO David W. Nassif sold 10,000 shares of the company’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $30.31, for a total transaction of $303,100.00. Following the sale, the chief financial officer owned 120,300 shares in the company, valued at approximately $3,646,293. This represents a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Anna Nijdam sold 2,670 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $30.87, for a total value of $82,422.90. Following the completion of the transaction, the insider owned 46,275 shares of the company’s stock, valued at approximately $1,428,509.25. This represents a 5.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 215,209 shares of company stock valued at $6,431,945 in the last quarter. 11.84% of the stock is currently owned by corporate insiders.

Institutional Trading of Pharvaris

A number of large investors have recently added to or reduced their stakes in PHVS. General Atlantic L.P. raised its stake in Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after buying an additional 500,000 shares during the period. Foresite Capital Management IV LLC boosted its holdings in shares of Pharvaris by 8.3% during the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after acquiring an additional 368,000 shares during the period. venBio Partners LLC grew its position in shares of Pharvaris by 8.2% in the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after purchasing an additional 350,000 shares during the last quarter. Deerfield Management Company L.P. increased its stake in shares of Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after purchasing an additional 425,000 shares during the period. Finally, Commodore Capital LP increased its stake in shares of Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after purchasing an additional 507,043 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.